Liver concerns scupper Takeda's fasiglifam at Phase III
This article was originally published in Scrip
Executive Summary
Despite the release of promising initial Phase III efficacy data earlier in the year, 2013 has not ended well for Takeda's first-in-class GPR40 agonist fasiglifam (TAK-875), with the company deciding to drop the oral diabetes drug for safety reasons.